---
title: "Sutro Biopharma, Inc. (STRO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/STRO.US.md"
symbol: "STRO.US"
name: "Sutro Biopharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T04:36:30.982Z"
locales:
  - [en](https://longbridge.com/en/quote/STRO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/STRO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/STRO.US.md)
---

# Sutro Biopharma, Inc. (STRO.US)

## Company Overview

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.sutrobio.com](https://www.sutrobio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.49)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 117 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 49.94% |  |
| Net Profit YoY | 37.36% |  |
| P/B Ratio | -7.84 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 524684427.46 |  |
| Revenue | 99608000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 331.40% | A |
| Profit Margin | -154.21% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 49.94% | A |
| Net Profit YoY | 37.36% | B |
| Total Assets YoY | -24.72% | E |
| Net Assets YoY | -159.14% | E |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 49.94% | A |
| Turnover | 0.35 | D |
| Gearing Ratio | 127.64% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sutro Biopharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "49.94%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "37.36%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-7.84",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "524684427.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "99608000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "331.40%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-154.21%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "49.94%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "37.36%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-24.72%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-159.14%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "49.94%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "127.64%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.42 | 319/386 | - | - | - |
| PB | -7.84 | 517/386 | - | - | - |
| PS (TTM) | 5.27 | 113/386 | 3.31 | 1.02 | 0.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 82% |
| Overweight | 1 | 9% |
| Underweight | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 31.67 |
| Highest Target | 55.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/STRO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/STRO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/STRO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/STRO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**